R Contains Benzene Ring Patents (Class 514/617)
-
Patent number: 11840497Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.Type: GrantFiled: February 22, 2021Date of Patent: December 12, 2023Assignee: PTC Therapeutics, Inc.Inventors: Orion D. Jankowski, Kieron E. Wesson, Paul Mollard, William D. Shrader
-
Patent number: 11673855Abstract: Provided herein are radiolabeled compounds useful for minimally invasive imaging techniques. An exemplary radiolabeled compound provided herein is useful as a radiotracer for position emission tomography imaging of voltage gated sodium channels. Methods for prepared unlabeled and labeled compounds, and diagnostic methods using the compounds are also provided.Type: GrantFiled: August 5, 2021Date of Patent: June 13, 2023Assignee: The General Hospital CorporationInventors: Matthias Schoenberger, Jacob Hooker
-
Patent number: 11660298Abstract: The present invention comprises a method of use of Icilin as a pre-treatment to mitigate the negative effects of extreme thermal trauma to skin tissue on a cellular level. Pre-treatment with Icilin prior to exposure to a thermal trauma event is shown to improve cellular viability, reduce pro-inflammatory cytokine levels, and reduce Reactive Oxygen Species (ROS) levels. The treatment is designed to be administered in small doses at concentrations of 0.0002-0.02 nM dissolved in an aprotic polar solvent such as dimethyl sulfoxide.Type: GrantFiled: August 1, 2020Date of Patent: May 30, 2023Inventor: Kevin Chew
-
Patent number: 11479532Abstract: Disclosed herein, are 5-Aminolevulinate synthase inhibitors and methods for their use in the treatment of porphyria.Type: GrantFiled: June 21, 2018Date of Patent: October 25, 2022Assignee: University of South FloridaInventors: Roman Manetsch, Gloria C. Ferreira, Bosko M. Stojanovski, Katya Pavlova Nacheva
-
Patent number: 11439607Abstract: A method is disclosed of treating pain with senicapoc, a potent Ca2+-activated K+ channel, KCa3.1 antagonist in CNS-resident microglia. Senicapoc is shown to cause in a decrease of IL-1? and NO release from microglia cells vivo and in vitro. Because of contribution of KCa3.1 to neuropathological processes, senicapoc is useful in the treatment of chronic, neuropathic, visceral, and inflammatory pain and the reversal of tactile allodynia.Type: GrantFiled: October 23, 2017Date of Patent: September 13, 2022Assignee: Paracelsus Neuroscience I, LLCInventors: Roland Staal, Thomas Möller
-
Patent number: 11434190Abstract: Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.Type: GrantFiled: December 21, 2017Date of Patent: September 6, 2022Assignee: THE UNIVERSITY OF QUEENSLANDInventors: Mathias Francois, Johannes Zuegg, Jeroen Overman, Sreeman Kumar Mamidyala, Angela Aguslyarti Salim, Frank Roger Fontaine, Matthew Allister Cooper, Robert John Capon, Avril Alexis Barbara Robertson
-
Agrochemical suspension concentrate comprising an alkoxylated alcohol dissolved in the aqueous phase
Patent number: 11375712Abstract: The present invention relates to an agrochemical aqueous suspension concentrate comprising a pesticide in the form of pesticide particles and at least 5 wt % of an adjuvant dissolved in the aqueous phase, wherein the adjuvant is of the formula (I) as defined herein. The invention also relates to the adjuvant as defined in formula (I). Furthermore, the invention relates to a process for the preparation of the suspension concentrate by contacting water, the pesticide, and the adjuvant. The present invention further relates to a method of controlling phytopathogenic fungi and/or undesired plant growth and/or undesired insect or mite attack and/or for regulating the growth of plants.Type: GrantFiled: August 6, 2015Date of Patent: July 5, 2022Assignee: BASF SEInventors: Klaus Kolb, Katja Marxer, Anja Simon, Rainer Berghaus -
Patent number: 11241427Abstract: Disclosed are compounds useful for alteration of NR2F6 activity. In some embodiments of the invention compounds disclosed are utilized for stimulation of NR2F6 activity, alone, or in combination with PKC activation. In other embodiments, the invention teaches use of compounds for inhibition of NR2F6 activation. Stimulation of NR2F6 within the context of the invention is useful, intra alia, for induction of immune inhibition, or stimulation of cellular proliferation without significant induction of differentiation. Inhibition of NR2F6 is desired in situations where the practitioner of the invention seeks to augment immune response, or induce cellular differentiation. In another embodiment, inhibition of NR2F6 expression is desired in situations where inhibition of cancer or cancer stem cells is needed.Type: GrantFiled: November 29, 2016Date of Patent: February 8, 2022Assignee: KCL Therapeutics, Inc.Inventors: David Koos, Thomas Ichim
-
Patent number: 11236042Abstract: A cooling agent composition includes a methyl menthol derivative represented by the following general formula (1). In the formula (1), a symbol * indicates an asymmetric carbon atom, X represents a hydrogen atom or a substituent, and Y represents an aryl group having 6 to 20 carbon atoms which may have a substituent.Type: GrantFiled: January 9, 2018Date of Patent: February 1, 2022Assignee: TAKASAGO INTERNATIONAL CORPORATIONInventors: Hisanori Itoh, Takaji Matsumoto, Tomoharu Sato, Makoto Harada, Masaya Otake, Masashi Otsuka
-
Patent number: 11097009Abstract: The present invention provides: a histone modification control agent for activating expression of a specific gene, i.e., a complex including a histone acetylation enzyme activator useful as an agent for activating a specific gene, and a polyamide for recognizing a regulatory region of a target gene; and a method for manufacturing the same. This complex specifically activates a group of genes relating to maintenance and/or differentiation of stem cells or precursor cells.Type: GrantFiled: February 12, 2016Date of Patent: August 24, 2021Assignee: KYOTO UNIVERSITYInventors: Hiroshi Sugiyama, Toshikazu Bando
-
Patent number: 10953007Abstract: The present invention includes compounds useful as modulators of TRPM8, such as compounds of Formula (I) and the subgenus and species thereof; personal products containing those compounds; and the use of those compounds and the personal products, particularly the use of increasing or inducing chemesthetic sensations, such as cooling or cold sensations.Type: GrantFiled: May 31, 2018Date of Patent: March 23, 2021Assignee: Firmenich IncorporatedInventors: Chad Priest, Alain Noncovich, Andrew Patron, Jane Ung
-
Patent number: 10836821Abstract: There is disclosed an improved ADC (antibody drug conjugate) type composition having at least two different drug payloads conjugated to a single targeting protein. More specifically, the present disclosure attaches a first drug conjugate to a dual Cysteine residue on a targeting protein and a second drug conjugate with a different drug to a Lys residue on the targeting protein.Type: GrantFiled: October 15, 2014Date of Patent: November 17, 2020Assignee: Sorrento Therapeutics, Inc.Inventors: Zhenwei Miao, Gang Chen, Tong Zhu, Alisher B. Khasanov, Yufeng Hong, Hong D. Zhang, Alexander Chucholowski
-
Patent number: 10774120Abstract: The disclosure pertains to conformational epitopes in A-beta, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.Type: GrantFiled: November 9, 2016Date of Patent: September 15, 2020Assignee: The University of British ColumbiaInventors: Neil R. Cashman, Steven S. Plotkin
-
Patent number: 10759837Abstract: The disclosure pertains to epitopes identified in A-beta including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.Type: GrantFiled: November 9, 2016Date of Patent: September 1, 2020Assignee: The University of British ColumbiaInventors: Neil R. Cashman, Steven S. Plotkin
-
Patent number: 10526307Abstract: Disclosed are compounds, for example, compounds of formula (I), (Formula (I) wherein R, R0, R1-R8, n, X, Y, Y?, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.Type: GrantFiled: December 16, 2015Date of Patent: January 7, 2020Assignee: ADT Pharmaceuticals, LLCInventors: Gary A. Piazza, Xi Chen, Adam B. Keeton, Michael R. Boyd
-
Patent number: 10449167Abstract: The invention relates to a kind of medicinal salts of polyamine derivatives, preparation method and use thereof in preparation of a drug for treating sepsis. These novel compounds have good antagonistic action on a plurality of pathogen-associated molecular patterns that induce sepsis, such as bacterial lipopolysaccharide (endotoxin), bacterial genomic DNA, peptidoglycan, lipoteichoic acid, virus RNA, and zymosan, and can be used for preparation of a drug for treating sepsis.Type: GrantFiled: October 28, 2016Date of Patent: October 22, 2019Assignee: Chongqing Antixin Biotechnology Co., LTD.Inventors: Yue Zheng, Jun Deng, Qingguang Liu
-
Patent number: 10052335Abstract: Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17?-acetoxy-19-norpregn-4-ene-3,20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration.Type: GrantFiled: October 19, 2010Date of Patent: August 21, 2018Assignee: The Population Council, Inc.Inventors: Regine Sitruk-Ware, Michael Maria Helmut Schumacher, Roberta Brinton, Martine El-Etr, Abdelmouman Ghoumari, Rachida Guennoun
-
Patent number: 9883997Abstract: The invention is directed to a cosmetic composition and the precursor thereof. The composition has solid agent and liquid agent, both of which are cosmetic benefit ingredients. The solubility of solid agents in liquid agents in the inventive compositions is enhanced in the presence of a tricyclodecane amide.Type: GrantFiled: March 10, 2014Date of Patent: February 6, 2018Assignee: Conopco, Inc.Inventors: Bijan Harichian, Teanoosh Moaddel, Ian Stuart Cloudsdale, Van Au, Jianming Lee, John Kenneth Dickson, Jr.
-
Patent number: 9381173Abstract: Isolated stereoisomeric forms of the compound (S)2-N(3-O-(propan 2-ol) -1-propyl-4-hydroxybenzene)-3-phenylpropylamide and uses in the treatment of pain.Type: GrantFiled: May 30, 2014Date of Patent: July 5, 2016Assignee: Novaremed Ltd.Inventor: Eliahu Kaplan
-
Patent number: 9301940Abstract: The invention features compounds that have antibacterial activity, their use for the treatment of bacterial infections, screening methods that use whole animals or plant seedlings to identify compounds that inhibit a pathogen in the animal or plant, and screening methods to identify compounds that increase the lifespan of an organism.Type: GrantFiled: June 18, 2007Date of Patent: April 5, 2016Assignees: The General Hospital Corporation, Northeastern UniversityInventors: Frederick M. Ausubel, Kim Lewis, Terence I. Moy, Suresh Gopalan
-
Patent number: 9204638Abstract: The present invention relates to a method of increasing yield of a plant. This method involves applying to a plant and/or area of cultivation thiophanate methyl and an isolated hypersensitive response elicitor protein or polypeptide fragment, wherein said applying is carried out under conditions effective to induce a synergistic yield from the plant. The present invention also relates to a composition comprising a liquid or solid carrier, thiophanate methyl, and an isolated hypersensitive response elicitor protein or polypeptide fragment.Type: GrantFiled: December 28, 2012Date of Patent: December 8, 2015Assignee: Plant Health Care, Inc.Inventor: Zhongmin Wei
-
Patent number: 9199917Abstract: Compounds for use in the treatment or prophylaxis of pain, including acute and chronic pain (e.g., nociceptive pain, neuropathic pain, headaches, migraine), represented by general formula (I) in which: the dotted line represents a single or a double bond; and R5 and R5? are independently —H, —OH or —OR6, where R6 is a linear or branched C1-C4 alkyl; X is -0-, —CH2O—, —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; Z is —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; m is an integer of O or 1; and n is an integer of 0-50. The compounds of the invention are also effective for reducing inflammation and may be used alone or in combination with other analgesics.Type: GrantFiled: October 7, 2014Date of Patent: December 1, 2015Assignee: Novaremed LimitedInventor: Eliahu Kaplan
-
Patent number: 9169196Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.Type: GrantFiled: June 21, 2013Date of Patent: October 27, 2015Assignee: Edison Pharmaceuticals, Inc.Inventors: Orion D. Jankowski, Kieron E. Wesson, Paul Mollard, William D. Shrader
-
Patent number: 9132111Abstract: Disclosed are topical antimicrobial compositions. The compositions are useful for disinfecting and treating microbial infections of the skin or mucosa of humans and animals.Type: GrantFiled: May 13, 2011Date of Patent: September 15, 2015Inventors: Kewang Lu, Hoshun Luk, Lei Zhang
-
Patent number: 9051240Abstract: Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly useful for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases.Type: GrantFiled: March 11, 2013Date of Patent: June 9, 2015Assignee: Newron Pharmaceuticals S.P.A.Inventors: Piero Melloni, Alessandra Restivo, Emanuela Izzo, Simona Francisconi, Elena Colombo, Cibele Sabido-David
-
Publication number: 20150133540Abstract: Control or repellency of mosquitoes is accomplished by bringing the insects into contact with at least one of the compounds of the structure (I) wherein R is selected from —OH, ?O, —OC(O)R4, —OR6, —(OR6)2, wherein each R6 is independently selected from an alkyl group containing from 1 to 4 carbon atoms and R4 is a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; X is O or CH2, with the proviso that when X is O R can only be ?O; each Z is independently selected from (CH) and (CH2); y is a numeral selected from 1 and 2; R1 is selected from H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; R2 is selected from H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 15 carbon atoms; R3 is selected from the group consisting of H and a branched or straight chain, saturType: ApplicationFiled: April 30, 2013Publication date: May 14, 2015Inventor: Robert H. Bedoukian
-
Publication number: 20150133406Abstract: Control or repellency of biting arthropods, particularly biting insects, is accomplished by bringing the biting arthropods into contact with combinations of compounds identical or related to those found on human/animal skin or in plants acting synergistically with one another, or in combination with conventional repellents like DEET®, para-menthane-3,8-diol (PMD), sec-butyl-2-(2-hydroxyethyl) piperidine carboxylate (“Picaridin”), or other nitrogen containing repellents selected from amines, amides and nitrogen containing heterocyclic compounds, or any synergistic combination of DEET®, PMD, Picaridin, or other nitrogen containing repellents selected from amines, amides and nitrogen containing heterocyclic compounds.Type: ApplicationFiled: November 13, 2014Publication date: May 14, 2015Inventor: Robert H. BEDOUKIAN
-
Patent number: 9029293Abstract: An inhibitor for tobacco axillary bud growth, the inhibitor containing one or more cell division inhibitors selected from pyridine-based compounds and benzamide-based compounds. This inhibitor may further include an aliphatic alcohol having 6 to 20 carbon atoms in combination with the one or more cell division inhibitors.Type: GrantFiled: June 13, 2011Date of Patent: May 12, 2015Assignee: SDS Biotech K.K.Inventors: Motoki Tanaka, Keijitsu Tanaka, Takeshi Shibuya, Eiji Ikuta, Kotaro Yoshinaga, Yuki Yamaguchi
-
Publication number: 20150126493Abstract: The invention provides bicyclic sulfone compounds, pharmaceutical compositions, methods of inhibiting RORy activity, reducing the amount of iL-17 in a subject, and treating immune disorders and inflammatory disorders using such bicyclic sulfone compounds. Another aspect of the invention provides a method of treating a subject suffering from a medical disorder. The method comprises administering to the subject a therapeutically effective amount of one or more bicyclic sulfone compounds described herein. In certain other embodiments, the disorder is rheumatoid arthritis.Type: ApplicationFiled: May 3, 2013Publication date: May 7, 2015Inventors: Thomas D. Aicher, Kenneth J. Barr, Vladimir Simov, Willam D. Thomas, Peter L. Toogood, Chad A. Van Huis
-
Publication number: 20150126572Abstract: A method for treating a patient having ASD is disclosed. The method includes administering to the patient a plurality of comestible units, e.g., cookies, cumulatively comprising a therapeutically effective amount of inositol. The method may further include administering to the patient a therapeutically effective amount of an alpha-2 adrenergic agonist in an extended release dosage form.Type: ApplicationFiled: January 14, 2015Publication date: May 7, 2015Inventor: Richard Louis Price
-
Publication number: 20150111749Abstract: Methods and compositions for controlling plant pests, particularly weeds and/or plant phytopathogens using sarmentine and/or analogs thereof are disclosed.Type: ApplicationFiled: December 31, 2014Publication date: April 23, 2015Inventors: Huazhang Huang, Ratnakar Asolkar
-
Publication number: 20150105349Abstract: Short-chain 2- to 3-carbon alcohols are used as solvents for cooling agents in the preparation of topical therapeutic and cosmetic formulations. Some of these alcohols, especially ethanol, inhibit the ability of the cooling agent to activate its target receptor. In one embodiment of this invention, (R)-1,2-propanediol is used as an alcoholic solvent for the topical delivery of cooling agents to biological surfaces. This (R)-1,2-propanediol enantiomer has a minimum inhibitory effect on cooling with respect to standard 2- to 3-carbon alcoholic solvents, and functions to substantially protect the agents cooling activity from inhibition when in the presence of a short-chain alcohol such as ethanol.Type: ApplicationFiled: August 19, 2013Publication date: April 16, 2015Inventor: Edward T. Wei
-
Patent number: 8993581Abstract: Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.Type: GrantFiled: June 11, 2013Date of Patent: March 31, 2015Assignee: Trustees of Boston UniversityInventors: Susan Perrine, Douglas Faller
-
Publication number: 20150087712Abstract: The present invention relates to methods for reducing testosterone levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC), metastatic castration resistant prostate cancer (mCRPC), and methods of reducing high or increasing PSA levels and/or increasing SHBG levels in a subject suffering from prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC). The compounds of this invention suppress free or total testosterone levels despite castrate levels secondary to ADT and reduce high or increasing PSA levels. This reduction in testosterone levels may be used to treat prostate cancer, advanced prostate cancer, CRPC and mCRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia.Type: ApplicationFiled: October 24, 2014Publication date: March 26, 2015Inventors: James T. Dalton, Mitchell S. Steiner, Christopher C. Coss, Robert H. Getzenberg
-
Publication number: 20150080473Abstract: Compounds for use in the treatment or prophylaxis of pain, including acute and chronic pain (e.g., nociceptive pain, neuropathic pain, headaches, migraine), represented by general formula (I) in which: the dotted line represents a single or a double bond; and R5 and R5? are independently —H, —OH or —OR6, where R6 is a linear or branched C1-C4 alkyl; X is -0-, —CH2O—, —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; Z is —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; m is an integer of O or 1; and n is an integer of 0-50. The compounds of the invention are also effective for reducing inflammation and may be used alone or in combination with other analgesics.Type: ApplicationFiled: October 7, 2014Publication date: March 19, 2015Inventor: Eliahu Kaplan
-
Publication number: 20150045213Abstract: Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides.Type: ApplicationFiled: March 6, 2013Publication date: February 12, 2015Inventors: Anthony Cornelis O'Sullivan, Olivier Loiseleur, Roman Staiger, Torsten Luksch, Thomas Pitterna
-
Publication number: 20150023889Abstract: Disclosed are compounds, compositions, and methods relating to fluoride aptamers, fluoride-responsive riboswitches, fluoride-regulated expression constructs, fluoride transporters, nucleic acids encoding fluoride transporters, expression constructs encoding fluoride transporters, and cells containing or including any combination of these.Type: ApplicationFiled: September 17, 2012Publication date: January 22, 2015Inventors: Ronald Breaker, Jenny Baker, Narasimhan Sudarsan, Zasha Weinberg, Adam Roth, Tyler Ames, James Nelson
-
Publication number: 20150023921Abstract: The present invention relates to novel compositions having anti-viral activity and in particular it relates to synergistic compositions active against Hepatitis C virus (HCV). The invention also relates to methods for retarding, reducing or otherwise inhibiting HCV growth and/or functional activity.Type: ApplicationFiled: April 3, 2014Publication date: January 22, 2015Applicant: BIOTRON LIMITEDInventors: Gary Dinneen EWART, Carolyn Anne LUSCOMBE, Michelle MILLER
-
Publication number: 20150010635Abstract: Controlled release particles are obtained by dissolving a hydrophobic antibiotic compound with a hydrophobic polymerizable vinyl monomer to prepare a hydrophobic solution, blending water with an emulsifier to prepare an aqueous emulsifier solution, emulsifying the hydrophobic solution in the aqueous emulsifier solution, and polymerizing the polymerizable vinyl monomer by mini-emulsion polymerization in the presence of a polymerization initiator, thereby producing a polymer containing an antibiotic compound and having an average particle size of below 1 ?m.Type: ApplicationFiled: December 27, 2012Publication date: January 8, 2015Applicant: Japan EnviroChemicals, Ltd.Inventors: Junji Oshima, Hideaki Inoue
-
Publication number: 20150011516Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.Type: ApplicationFiled: July 21, 2014Publication date: January 8, 2015Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Tonos de Leon, Heather A. Balsiger, Robert Fletterick
-
Patent number: 8927605Abstract: The invention relates to a TRPM8 modulator for achieving a cooling effect on the skin or a mucous membrane.Type: GrantFiled: November 22, 2010Date of Patent: January 6, 2015Assignees: Symrise AG, BASF SEInventors: Thomas Subkowski, Michael Backes, Heiko Oertling, Arnold Machinek, Hubert Loges, Ulrike Simchen, Horst Surburg, Claus Bollschweiler, Jens Wittenberg, Wolfgang Siegel
-
Publication number: 20150005320Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein X, Y, A, Z, L and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions and immune disorders.Type: ApplicationFiled: September 27, 2013Publication date: January 1, 2015Applicant: Synta Pharmaceuticals Corp.Inventors: Yu Xie, Mats Holmqvist, Jerome Mahiou, Mitsunori Ono, Lijun Sun, Shoujun Chen, Shijie Zhang, Jun Jiang, Dinesh Chimmanamada, Chih-Yi Yu
-
Publication number: 20140378461Abstract: Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides.Type: ApplicationFiled: February 14, 2013Publication date: December 25, 2014Applicant: SYNGENTA PARTICIPATIONS AGInventors: Anthony Cornelius O'Sullivan, Olivier Loiseleur, Daniel Stierli, Torsten Luksch, Thomas Pitterna
-
Patent number: 8916550Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.Type: GrantFiled: November 15, 2006Date of Patent: December 23, 2014Assignee: Hydra Biosciences, Inc.Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, Jr., Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen, Anu Mahadevan, Peter Meltzer
-
Publication number: 20140356290Abstract: Methods for therapeutic renal denervation are disclosed herein. One aspect of the present application, for example, is directed to methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry several therapeutic benefits across many disease states.Type: ApplicationFiled: June 6, 2014Publication date: December 4, 2014Inventors: Neil Barman, Howard Levin, Paul Sobotka, Mark Gelfand
-
Publication number: 20140350099Abstract: Compounds for use in the treatment or prophylaxis of pain, including acute and chronic pain (e.g., nociceptive pain, neuropathic pain, headaches, migraine), represented by general formula I: in which: the dotted line represents a single or a double bond; and R5 and R5? are independently —H, —OH or —OR6, where R6 is a linear or branched C1-C4 alkyl; X is —CH2O—; Z is —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; m is 1; and n is an integer of 1-5. The compounds of the invention are also effective for reducing inflammation and may be used alone or in combination with other analgesics.Type: ApplicationFiled: July 21, 2014Publication date: November 27, 2014Inventor: Eliahu Kaplan
-
Publication number: 20140343108Abstract: The present invention belongs to the field of natural medicine and pharmaceutical chemistry, and specifically relates to novel amidated derivatives of oleanolic acid according to formula (I) or a pharmaceutically acceptable salt thereof, to a process for the preparation of these compounds, compositions containing such compounds and their use in preparing antineoplastic medicaments.Type: ApplicationFiled: November 30, 2012Publication date: November 20, 2014Inventors: Frank Rong, Rongzhen Xu, Fuwen Xie, Hongxi Lai
-
Patent number: 8889731Abstract: This invention relates to compositions of one or more compounds that incorporate one or more allyl sulfide, allyl disulfide or allyl polysulfide moieties, or one or more allyl sulfide, allyl disulfide or allyl polysulfide moieties and one or more hydroxyl groups, used in effective amount in formulations, including emulsions, to repel blood-feeding ectoparasitic arthropods, including mosquitoes, and to deter them from landing and feeding when applied to the skin, clothing or environment of animals, including humans. Said compounds can include, but are not limited to, 8-allyl-sulfanyloctan-1-ol. This invention also relates to compositions comprising one or more of said compounds in further combination with other arthropod repellent and deterrent compounds, including vanillin. These compounds may be formulated with inert ingredients to form a liquid, gel, paste, soap, spray, aerosol or powder.Type: GrantFiled: March 28, 2008Date of Patent: November 18, 2014Assignee: Contech Enterprises Inc.Inventors: Regine M. Gries, Gerhard G. Gries, Grigori Khaskin, Norman Avelino, Cory Campbell
-
Patent number: 8883853Abstract: Compounds for use in the treatment or prophylaxis of pain, including acute and chronic pain (e.g., nociceptive pain, neuropathic pain, headaches, migraine), represented by general formula (I) in which: the dotted line represents a single or a double bond; and R5 and R5? are independently —H, —OH or —OR6, where R6 is a linear or branched C1-C4 alkyl; X is -0-, —CH2O—, —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; Z is —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; m is an integer of O or 1; and n is an integer of 0-50. The compounds of the invention are also effective for reducing inflammation and may be used alone or in combination with other analgesics.Type: GrantFiled: March 6, 2009Date of Patent: November 11, 2014Assignee: Novaremed LimitedInventor: Eliahu Kaplan
-
Publication number: 20140329860Abstract: Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-substituted-p-quinone derivatives as disclosed herein.Type: ApplicationFiled: March 24, 2014Publication date: November 6, 2014Applicant: Edison Pharmaceuticals, Inc.Inventors: Andrew W. Hinman, Kieron E. Wesson, Orion D. Jankowski, Paul Mollard, William D. Shrader, Christopher R. Cornell